Emergent Inks Deal to Manufacture Providence’s COVID-19 Vaccine

Gaithersburg, Md.-based Emergent BioSolutions has struck a five-year deal with Providence Therapeutics to help manufacture the Canadian company’s COVID-19 vaccine candidate.

The $90 million deal will cover contract manufacturing services, global supply chain studies and investments in facility and equipment at Emergent’s plant in Winnipeg, Manitoba. And additional process and analytical development services will be provided at Emergent’s Gaithersburg facility.

Manufacturing is set to begin next year, when Emergent will begin production of “tens of millions of doses” of Providence’s investigational messenger RNA-based vaccine, PTX-COVID19-B, in addition to batches of PTX-COVID19-B formulated bulk drug substance.